PharmaCorp Rx Inc. (TSXV:PCRX)

PharmaCorp Rx Statistics

Total Valuation

PharmaCorp Rx has a market cap or net worth of CAD 55.72 million. The enterprise value is 47.26 million.

Market Cap	55.72M
Enterprise Value	47.26M

Important Dates

The next estimated earnings date is Friday, November 7, 2025.

Earnings Date	Nov 7, 2025
Ex-Dividend Date	n/a

Share Statistics

PharmaCorp Rx has 117.30 million shares outstanding. The number of shares has increased by 20.45% in one year.

Current Share Class	117.30M
Shares Outstanding	117.30M
Shares Change (YoY)	+20.45%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	13.35%
Owned by Institutions (%)	n/a
Float	101.64M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.01
PB Ratio	1.83
P/TBV Ratio	4.34
P/FCF Ratio	n/a
P/OCF Ratio	134.46
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-132.48
EV / Sales	3.40
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-27.30

Financial Position

The company has a current ratio of 5.58, with a Debt / Equity ratio of 0.03.

Current Ratio	5.58
Quick Ratio	4.77
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-0.51
Interest Coverage	-23.35

Financial Efficiency

Return on equity (ROE) is -1.46% and return on invested capital (ROIC) is -1.96%.

Return on Equity (ROE)	-1.46%
Return on Assets (ROA)	-1.80%
Return on Invested Capital (ROIC)	-1.96%
Return on Capital Employed (ROCE)	-2.59%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.47
Inventory Turnover	9.67

Taxes

In the past 12 months, PharmaCorp Rx has paid 159,485 in taxes.

Income Tax	159,485
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -30.43% in the last 52 weeks. The beta is -5.11, so PharmaCorp Rx's price volatility has been lower than the market average.

Beta (5Y)	-5.11
52-Week Price Change	-30.43%
50-Day Moving Average	0.48
200-Day Moving Average	0.50
Relative Strength Index (RSI)	51.19
Average Volume (20 Days)	29,631

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, PharmaCorp Rx had revenue of CAD 13.91 million and -356,770 in losses. Loss per share was -0.00.

Revenue	13.91M
Gross Profit	5.46M
Operating Income	-859,772
Pretax Income	-226,331
Net Income	-356,770
EBITDA	-308,997
EBIT	-859,772
Loss Per Share	-0.00

Balance Sheet

The company has 9.56 million in cash and 878,899 in debt, giving a net cash position of 8.68 million or 0.07 per share.

Cash & Cash Equivalents	9.56M
Total Debt	878,899
Net Cash	8.68M
Net Cash Per Share	0.07
Equity (Book Value)	30.43M
Book Value Per Share	0.26
Working Capital	9.81M

Cash Flow

In the last 12 months, operating cash flow was 414,371 and capital expenditures -2.15 million, giving a free cash flow of -1.73 million.

Operating Cash Flow	414,371
Capital Expenditures	-2.15M
Free Cash Flow	-1.73M
FCF Per Share	-0.01

Margins

Gross margin is 39.25%, with operating and profit margins of -6.18% and -2.57%.

Gross Margin	39.25%
Operating Margin	-6.18%
Pretax Margin	-1.63%
Profit Margin	-2.57%
EBITDA Margin	-2.22%
EBIT Margin	-6.18%
FCF Margin	n/a

Dividends & Yields

PharmaCorp Rx does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-20.45%
Shareholder Yield	n/a
Earnings Yield	-0.64%
FCF Yield	-3.11%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

PharmaCorp Rx has an Altman Z-Score of 7.97 and a Piotroski F-Score of 5.

Altman Z-Score	7.97
Piotroski F-Score	5